Schüpbach, W.M., Chastan, N., Welter, M.L., Houeto, J.L., Mesnage, V., Bonnet, A.M., Czernecki, V., Maltête, D., Hartmann, A., Mallet, L., Pidoux, B., Dormont, D., Navarro, S., Cornu, P., Mallet, A. and Agid, Y. (2005) Stimulation of the Subthalamic Nucleus in Parkinson’s Disease: A 5-Year Follow-Up. Journal of Neurology, Neurosurgery, and Psychiatry, 76, 1640-1644. http://dx.doi.org/10.1136/jnnp.2005.063206

has been cited by the following article:

• TITLE: Five-Year Outcomes of Bilateral Subthalamic Nucleus Stimulation in Japanese Patients with Parkinson’s Disease

  AUTHORS: Atsushi Umemura, Miwako Miyata, Yuichi Oka, Kenji Okita, Genko Oyama, Yasushi Shimo, Nobutaka Hattori

  KEYWORDS: Deep Brain Stimulation, Subthalamic Nucleus, Parkinson’s Disease, Long-Term Outcome, Adverse Effect

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.4 No.2, April 10, 2015

  ABSTRACT: Background: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is widely performed for medically refractory Parkinson’s disease (PD). Several western studies have examined the long-term outcomes of STN DBS. However, the long-term outcomes in Japanese patients have not been reported. Methods: We studied the long-term outcomes of STN DBS in Japanese patients with PD. Fifty-five consecutive patients treated with bilateral STN DBS were followed for 5 years after surgery. Each patient underwent Unified Parkinson’s Disease Rating Scale assessments preoperatively and 1 and 5 years after surgery. Results: Twelve patients (22%) were lost to follow up within 5 years. Among them, 7 died and 5 became bed ridden because of PD deterioration. In the 43 patients followed for 5 years, STN DBS significantly improved motor function. The cardinal motor symptoms of tremor, rigidity, and bradykinesia in medication-on periods were significantly better than baseline 5 years after DBS. However, axial motor symptoms of speech, gait and postural stability gradually deteriorated and significantly worsened 5 years after DBS. Motor complications, including dyskinesia and motor fluctuations, significantly improved after DBS with a marked reduction in dopaminergic medication. These effects were maintained 5 years after DBS. Frequently, persisting adverse effects included apraxia of eyelid opening and dysarthria. Conclusions: STN DBS significantly improved motor symptoms in patients with advanced PD. These effects were maintained over 5 years in most patients. However, some showed rapid PD progression even after STN DBS. Other treatments for the axial symptoms and disease progression are needed in long-term PD treatment.